Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

19 medicines in Sweden are under investigation in a major EMA inquiry

19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Am...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

”Sverige riskerar tappa forskartalanger – dags att bygga broar”

Debatten om arbetskraftsinvandring är het i Sverige. Men när vi diskuterar kvoter och restriktioner missar vi en avgörande aspekt: Vad händer med de internation...

EQT säljer Karo Healthcare för 27 miljarder

Riskkapitalbolaget KKR förvärvar det svenska konsumenthälsobolaget Karo Healthcare från EQT.

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

MSD köper Verona Pharma för 10 miljarder dollar

Läkemedelsjätten Merck & Co, känt som MSD utanför USA och Kanada, har ingått avtal om att förvärva Verona Pharma för cirka 10 miljarder dollar, motsvarande cirk...

Doge backar om nedläggning av viktigt FDA-labb

Trumpadministrationen drar efter kritik tillbaka beslutet att stänga ett av FDA:s viktigaste laboratorier för läkemedelskontroll.

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

USA upprättar databas över autismpatienter – ska forska kring orsakerna

USA:s hälsomyndigheter ska skapa en databas över autismpatienter för att kunna studera orsakerna till diagnosen. Det meddelade landets hälsominister Robert F. K...

"Unclear proposal from the EU Commission on how to solve the MDR challenges"

Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the avail...

BMS planerar investera nära 400 miljarder i USA

Under måndagen meddelade Bristol Myers Squibb att bolaget planerar att investera 40 miljarder dollar, motsvarande 387 miljarder svenska kronor, i USA under de k...

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

Meet us at Control 2025

Innovations that drive efficiency.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

RegSmart Life Science AB

Europeiska läkemedelsaktier rasar efter Trumps tullhot

Europeiska läkemedelsbolag faller kraftigt efter att USA:s president Donald Trump flaggat för att stora tullhöjningar är på gång mot branschen.